Pharmaceutical Technology

JUNE 1, 2023

Dipharma is a pioneer in developing improved generic pharmaceutical products for rare diseases: our desire to innovate and our engagement do not stop, but every day we continue to seek new and better solutions for patients around the world.”

FDA Approval 130

FDA Approval Generic Pharmaceutical Production Drugs 130

The Pharma Data

MARCH 22, 2023

The adalimumab citrate-free HCF (100 mg/mL) is approved to treat seven indications covered by the reference medicine, Humira ® * (adalimumab), including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis and plaque psoriasis.

FDA Approval 40

FDA Approval Generic Pharmaceutical Medicine Protein 40

The Pharma Data

MARCH 15, 2022

Agency Supports Development of Complex Generic Drug-Device Combination Product to Improve Competition and Access to More Affordable Medicines. The FDA regularly takes steps to help guide industry through the development process for generic drug products, including combination products, such as MDIs, that consist of a drug and a device.

FDA Approval 52

FDA Approval Generic Drugs Production Drugs 52

The Pharma Data

JUNE 17, 2022

At Sandoz, we are constantly looking for ways to meet the changing needs of patients and health care providers,” said Florian Bieber, Global Head Biopharmaceuticals Development, Sandoz. “By The adalimumab reference medicine (Humira ®* ) was first approved with an adalimumab concentration of 50 mg/mL.

Medicine 52

Medicine Generic Pharmaceutical FDA Approval Packaging 52

Pharmaceutical Technology

DECEMBER 22, 2022

The funding will offer capital to extend Blueprint’s varied pipeline toward marketing as well as to continue seeking strategic and synergistic business development prospects. billion to expedite research and development (R&D) for infectious diseases in lower-income countries. Innovation.

Insulin 130

Insulin Production Development Genetics 130

The Pharma Data

APRIL 4, 2023

It has a leading global portfolio with eight marketed biosimilars and a further 15+ in various stages of development. The adalimumab reference medicine (Humira ® *) was first approved with an adalimumab concentration of 50 mg/mL. About Sandoz Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars.

Medicine 40

Medicine Generic Pharmaceutical FDA Approval Marketing 40

XTalks

JUNE 8, 2022

Sandoz is a pioneering leader in generic pharmaceuticals and biosimilars, as Sandoz launched the world’s first biosimilar in Europe in 2006 and won the first biosimilar approval in the US in 2014. Related: Cyltezo Becomes First FDA-Approved Interchangeable Humira Biosimilar. billion in 2021 to a high of $44.7

Generic Pharmaceutical 69

Generic Pharmaceutical Branding Production Medicine 69